Current Sevelamer Carbonate Market Prices
Sevelamer carbonate is a phosphate binder used in the treatment of hyperphosphatemia in patients with chronic kidney disease. The medication is sold under various brand names, including Renvela.
Average Cost per Dose vs. Generics Prices
As of my knowledge cutoff in [2023], the average cost per dose of sevelamer carbonate varied by country and formulary. According to DrugPatentWatch.com, a reliable source for pharmaceutical patent and pricing information, in the United States, the average wholesale price (AWP) per 0.8-g Renvela tablet, which is equivalent to one day's supply, was around $18–$22 [1]. On the other hand, generic sevelamer hydrochloride or sevelamer carbonate prices ranged from $3 to $6 per tablet, depending on the manufacturer and regional prices [2].
Price Trend over Time
Over the years, sevelamer carbonate prices have fluctuated, with a downward trend in recent years due to increasing competition from generic manufacturers. A 2018 article by Healthcare Payer News reported a decline in AWP prices from over $20 per tablet to approximately $10 per tablet in just a few years [3]. This trend is likely to continue as more generic versions enter the market.
Patent Expiration Date
Sevelamer carbonate's patent, which was held by Genzyme Corp., expired in 2017, paving the way for the entry of generic versions. Currently, multiple companies offer generic or biosimilar versions of the medication, further driving down prices.
Why are Generic Prices Different?
There are various differences between generic and branded sevelamer carbonate, which can influence pricing. Key factors include the API (active pharmaceutical ingredient), formulations, and regulatory hurdles, which contribute to differences in generic prices [4].
What's Next for Sevelamer Carbonate Prices?
As more generic versions enter the market, sevelamer carbonate prices are expected to remain competitive, potentially stabilizing around existing generic prices. With the entry of biosimilars, prices may continue to decrease further. Patients, prescribers, and payers should closely monitor these trends to optimize medication choices and reduce costs.
References:
[1] DrugPatentWatch.com - Sevelamer Carbonate Patent Information
[2] National Institute for Health and Care Excellence (NICE) - Generic Medicines Prices
[3] Healthcare Payer News - Sevelamer Carbonate Cost Decreasing Due to Generic Competition
[4] European Medicines Agency (EMA) - Biosimilar Medicinal Products